Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: john jansen who wrote (24)	8/18/1999 2:59:00 PM
From: Marty	Read Replies (1) \| Respond to of 204

Actually, you make a very good point. Things have changed since the secondary. There is a lot to be said for gaining the credibility they desperately need now in the marketplace. Presumably, they will get it in the scientific community when more of their test results are made public. I suppose the thought was that the credibility and the potential would transfer over to the marketplace. But, bottom-line, what they have done is already known in the scientific community and it has not transferred over at all to where it makes any difference to them or to any of us stockholders. The stock is at or below where it was at the beginning of the year. It certainly appears that their ability to raise more money via another secondary is badly damaged. Early high risk investors got screwed and all this while the drug is testing out better and better and they are getting closer to market. Their terrible public relations and/or unwillingness or inability to communicate what they have has cost them and us a tremendous amount. At this point, "more of the same" is not going to get the company or the stockholders very far.